As Biotechnology companies, AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) and Akebia Therapeutics Inc. (NASDAQ:AKBA) are our subject to compare. And more specifically their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Demonstrates AMAG Pharmaceuticals Inc. and Akebia Therapeutics Inc. earnings per share, top-line revenue and valuation.

Profitability

Table 2 provides AMAG Pharmaceuticals Inc. and Akebia Therapeutics Inc.’s net margins, return on assets and return on equity.

Volatility & Risk

AMAG Pharmaceuticals Inc. is 59.00% less volatile than Standard and Poor’s 500 due to its 0.41 beta. Competitively, Akebia Therapeutics Inc.’s beta is 1.39 which is 39.00% more volatile than Standard and Poor’s 500.

Liquidity

AMAG Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 2.3 and 2.1 respectively. The Current Ratio and Quick Ratio of its competitor Akebia Therapeutics Inc. are 1.7 and 1.1 respectively. AMAG Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Akebia Therapeutics Inc.

Analyst Recommendations

The following table given below contains the ratings and recommendations for AMAG Pharmaceuticals Inc. and Akebia Therapeutics Inc.

AMAG Pharmaceuticals Inc. has a 25.70% upside potential and a consensus price target of $14.33. Competitively the average price target of Akebia Therapeutics Inc. is $16, which is potential 272.09% upside. The results provided earlier shows that Akebia Therapeutics Inc. appears more favorable than AMAG Pharmaceuticals Inc., based on analyst belief.

Institutional and Insider Ownership

Roughly 0% of AMAG Pharmaceuticals Inc. shares are held by institutional investors while 72.4% of Akebia Therapeutics Inc. are owned by institutional investors. Insiders held roughly 3.5% of AMAG Pharmaceuticals Inc.’s shares. Competitively, 1.4% are Akebia Therapeutics Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Akebia Therapeutics Inc. has weaker performance than AMAG Pharmaceuticals Inc.

Summary

Akebia Therapeutics Inc. beats on 5 of the 9 factors AMAG Pharmaceuticals Inc.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, Europe, China, and internationally, as well as with Mitsubishi Tanabe Pharma Corporation for the development and commercialization to vadadustat in Japan and other Asian countries. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.